Drug Trial Radar · NCT07633288
A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
Aug 1, 2027
Study completion Aug 1, 2027
Sponsor
- Lead sponsor
- SynAct Pharma ApsIndustry
- Sponsor type
- Industry
- First posted
- Jun 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in participants with respiratory insufficiency expected to be caused by respiratory viral infection.
Conditions
- Respiratory Viral Infection
Interventions
AP1189, 100 mgDrug
14 days of daily treatment of oral AP1189 100 mg as add-on to Standard of Care treatment
PlaceboDrug
14 days of daily treatment of AP1189 matching placebo as add-on to Standard of Care treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants meeting the composite endpoint, consisting of either death, invasive mechanical ventilation, ECMO, cardiovascular organ support, new occurrences of renal failure, hemofiltration or dialysis from baseline to day 28Time frame: 28 days
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
University Clinical Hospital Mostar, Clinic for Infectious Diseases
Mostar, Herzegovina-Neretva Canton, Bosnia and Herzegovina · Recruiting
University Clinical Center Republic of Srpska, Clinic for Infectious Diseases
Banja Luka, Republika Srpska, Bosnia and Herzegovina · Recruiting
University Clinical Centre Sarajevo, Clinic for Infectious Diseases
Sarajevo, Sarajevo Canton, Bosnia and Herzegovina · Recruiting
Clinical Center of Montenegro, Clinic for Infectious Diseases
Podgorica, Podgorica Municipality, Montenegro · Recruiting
Te Toka Tumai Auckland, Auckland City Hospital
Auckland, New Zealand · Recruiting
Aotearoa Clinical Trial Trust, Esme Green Building, Middlemore Hospital
Auckland, New Zealand · Recruiting
Christchurch Hospital, 2 Riccarton Avenue,
Christchurch, New Zealand · Not yet recruiting
MRINZ, 7 CSB Building, Wellington Hospital
Wellington, New Zealand · Recruiting
University Clinical Centre of Serbia, Clinic for Infectious Diseases
Belgrade, Serbia · Recruiting
University Clinical Centre Nis, Clinic for Infectious Diseases
Niš, Nišava District, Serbia · Recruiting
Health Center Uzice, General Hospital Uzice
Užice, Zlatibor District, Serbia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.